Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Gets Hep C Inhibitor With Potential Twice Daily Dosing From InterMune

This article was originally published in The Pink Sheet Daily

Executive Summary

Investigational compound ITMN-191 is a candidate for use in combination with Pegasys, Roche says.
Advertisement

Related Content

Roche Advances In HCV Protease Inhibitor Contest
Roche Advances In HCV Protease Inhibitor Contest
Abbott Wins Rights To Enanta’s Preclinical HCV Protease Inhibitors
Abbott Wins Rights To Enanta’s Preclinical HCV Protease Inhibitors
Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
Schering-Plough Takes The Long Road To Early Stage Hep C R&D
Novartis Bolsters Hep C Pipeline With Human Genome Sciences Collaboration
Novartis Bolsters Hep C Pipeline With Human Genome Sciences Collaboration

Topics

Advertisement
UsernamePublicRestriction

Register

PS063208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel